

Haojie Huang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8498505/publications.pdf>

Version: 2024-02-01

98
papers

7,353
citations

57758

44
h-index

56724

83
g-index

99
all docs

99
docs citations

99
times ranked

11121
citing authors

#	ARTICLE	IF	CITATIONS
1	Dynamic FoxO transcription factors. <i>Journal of Cell Science</i> , 2007, 120, 2479-2487.	2.0	991
2	Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 1649-1654.	7.1	470
3	CDK2-Dependent Phosphorylation of FOXO1 as an Apoptotic Response to DNA Damage. <i>Science</i> , 2006, 314, 294-297.	12.6	300
4	Hexokinase 2-Mediated Warburg Effect Is Required for PTEN- and p53-Deficiency-Driven Prostate Cancer Growth. <i>Cell Reports</i> , 2014, 8, 1461-1474.	6.4	233
5	Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. <i>Nature Cell Biology</i> , 2010, 12, 1108-1114.	10.3	230
6	Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT/mTORC1 activation. <i>Nature Medicine</i> , 2017, 23, 1055-1062.	30.7	225
7	Destruction of Full-Length Androgen Receptor by Wild-Type SPOP, but Not Prostate-Cancer-Associated Mutants. <i>Cell Reports</i> , 2014, 6, 657-669.	6.4	217
8	Measure transcript integrity using RNA-seq data. <i>BMC Bioinformatics</i> , 2016, 17, 58.	2.6	187
9	Regulation of FOXO protein stability via ubiquitination and proteasome degradation. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2011, 1813, 1961-1964.	4.1	180
10	Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer. <i>Cancer Research</i> , 2009, 69, 8386-8394.	0.9	179
11	Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF- κ B Activation and PD-L1 Expression. <i>Molecular Cell</i> , 2019, 73, 22-35.e6.	9.7	174
12	PTEN Induces Chemosensitivity in PTEN-mutated Prostate Cancer Cells by Suppression of Bcl-2 Expression. <i>Journal of Biological Chemistry</i> , 2001, 276, 38830-38836.	3.4	159
13	LncRNA <i>MALAT1</i> enhances oncogenic activities of EZH2 in castration-resistant prostate cancer. <i>Oncotarget</i> , 2015, 6, 41045-41055.	1.8	154
14	FOXO1 Inhibits Runx2 Transcriptional Activity and Prostate Cancer Cell Migration and Invasion. <i>Cancer Research</i> , 2011, 71, 3257-3267.	0.9	135
15	Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression. <i>European Urology</i> , 2018, 73, 322-339.	1.9	130
16	Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation. <i>Molecular Cell</i> , 2015, 59, 904-916.	9.7	129
17	Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance. <i>Clinical Cancer Research</i> , 2017, 23, 4704-4715.	7.0	117
18	DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4. <i>Molecular Cell</i> , 2018, 71, 592-605.e4.	9.7	114

#	ARTICLE	IF	CITATIONS
19	BRCA1 is a negative modulator of the PRC2 complex. <i>EMBO Journal</i> , 2013, 32, 1584-1597.	7.8	104
20	Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer. <i>Cell Reports</i> , 2016, 15, 599-610.	6.4	101
21	<scp>AKT</scp>â€phosphorylated <scp>FOXO</scp>1 suppresses <scp>ERK</scp> activation and chemoresistance by disrupting <scp>IQGAP</scp>1â€<scp>MAPK</scp> interaction. <i>EMBO Journal</i> , 2017, 36, 995-1010.	7.8	101
22	FOXO factors: a matter of life and death. <i>Future Oncology</i> , 2006, 2, 83-89.	2.4	89
23	MACE: model based analysis of ChIP-exo. <i>Nucleic Acids Research</i> , 2014, 42, e156-e156.	14.5	84
24	p300 Acetyltransferase Regulates Androgen Receptor Degradation and PTEN-Deficient Prostate Tumorigenesis. <i>Cancer Research</i> , 2014, 74, 1870-1880.	0.9	80
25	Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer. <i>Nucleic Acids Research</i> , 2018, 46, 1895-1911.	14.5	79
26	Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly. <i>Molecular Cancer</i> , 2019, 18, 170.	19.2	79
27	Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression. <i>Scientific Reports</i> , 2017, 7, 43864.	3.3	72
28	An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. <i>Nature Cell Biology</i> , 2021, 23, 1023-1034.	10.3	72
29	The Role of the Androgen Receptor in Prostate Cancer. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2002, 12, 193-208.	0.9	72
30	Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1â€MAPK Interaction. <i>Cancer Research</i> , 2017, 77, 4328-4341.	0.9	70
31	A Transcription-Independent Function of FOXO1 in Inhibition of Androgen-Independent Activation of the Androgen Receptor in Prostate Cancer Cells. <i>Cancer Research</i> , 2008, 68, 10290-10299.	0.9	62
32	Androgens Negatively Regulate Forkhead Transcription Factor FKHR (FOXO1) through a Proteolytic Mechanism in Prostate Cancer Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 13866-13877.	3.4	61
33	Modulation of Androgen Receptor by FOXA1 and FOXO1 Factors in Prostate Cancer. <i>International Journal of Biological Sciences</i> , 2014, 10, 614-619.	6.4	58
34	Isorhapontigenin (ISO) Inhibits Invasive Bladder Cancer Formation <i>In Vivo</i> and Human Bladder Cancer Invasion <i>In Vitro</i> by Targeting STAT1/FOXO1 Axis. <i>Cancer Prevention Research</i> , 2016, 9, 567-580.	1.5	58
35	The Cistrome and Gene Signature of Androgen Receptor Splice Variants in Castration Resistant Prostate Cancer Cells. <i>Journal of Urology</i> , 2015, 193, 690-698.	0.4	57
36	The novel BETâ€CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wildâ€type prostate cancer. <i>EMBO Molecular Medicine</i> , 2019, 11, e10659.	6.9	56

#	ARTICLE	IF	CITATIONS
37	Destruction of DNA-Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG. <i>Advanced Science</i> , 2021, 8, e2102555.	11.2	56
38	<sc>EZH</sc> 2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis. <i>EMBO Journal</i> , 2019, 38, .	7.8	55
39	Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer. <i>PLoS Genetics</i> , 2017, 13, e1006748.	3.5	54
40	Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1734-1743.	7.0	54
41	Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1210, 319-331.	1.6	54
42	Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion. <i>Cancer Research</i> , 2017, 77, 6524-6537.	0.9	51
43	<i>TMPRSS2-ERG</i> Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in <i>PTEN</i> and <i>TP53</i>-Mutated Prostate Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4551-4565.	7.0	51
44	PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 834-846.	7.0	48
45	FOXA1 overexpression suppresses interferon signaling and immune response in cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	48
46	Androgens repress Bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cells. <i>Oncogene</i> , 2004, 23, 2161-2176.	5.9	47
47	Phosphorylation of EZH2 by CDK1 and CDK2. <i>Cell Cycle</i> , 2011, 10, 579-583.	2.6	47
48	CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers. <i>Cancers</i> , 2021, 13, 2872.	3.7	45
49	Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer. <i>Oncotarget</i> , 2016, 7, 3440-3452.	1.8	45
50	P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth. <i>Oncotarget</i> , 2016, 7, 15135-15149.	1.8	45
51	A noncanonical AR addiction drives enzalutamide resistance in prostate cancer. <i>Nature Communications</i> , 2021, 12, 1521.	12.8	43
52	BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion. <i>Oncotarget</i> , 2016, 7, 38319-38332.	1.8	43
53	Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 5262.	12.8	40
54	Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	40

#	ARTICLE	IF	CITATIONS
55	CBP Loss Cooperates with PTEN Haploinsufficiency to Drive Prostate Cancer: Implications for Epigenetic Therapy. <i>Cancer Research</i> , 2014, 74, 2050-2061.	0.9	39
56	Dual inhibition of <i>AKT</i> and <i>TOR</i> signaling by targeting <i>HDAC3</i> in <i>PTEN</i> -mutated prostate cancer. <i>EMBO Molecular Medicine</i> , 2018, 10, .	6.9	39
57	Prevalent Homozygous Deletions of Type I Interferon and Defensin Genes in Human Cancers Associate with Immunotherapy Resistance. <i>Clinical Cancer Research</i> , 2018, 24, 3299-3308.	7.0	37
58	Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer. <i>Oncotarget</i> , 2016, 7, 38551-38565.	1.8	36
59	KCTD12 Regulates Colorectal Cancer Cell Stemness through the ERK Pathway. <i>Scientific Reports</i> , 2016, 6, 20460.	3.3	34
60	HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4/6 Inhibitor Resistance in Cancer. <i>Cancer Research</i> , 2021, 81, 1486-1499.	0.9	34
61	Posttranslational regulation of androgen dependent and independent androgen receptor activities in prostate cancer. <i>Asian Journal of Urology</i> , 2020, 7, 203-218.	1.2	33
62	A novel highly potent trivalent TGF- β 2 receptor trap inhibits early-stage tumorigenesis and tumor cell invasion in murine <i>Pten</i> -deficient prostate glands. <i>Oncotarget</i> , 2016, 7, 86087-86102.	1.8	32
63	DNA Damage Promotes TMPRSS2-ERG Oncoprotein Destruction and Prostate Cancer Suppression via Signaling Converged by GSK3 β and WEE1. <i>Molecular Cell</i> , 2020, 79, 1008-1023.e4.	9.7	32
64	Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer. <i>Oncogene</i> , 2020, 39, 6556-6571.	5.9	29
65	Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity. <i>Theranostics</i> , 2020, 10, 1033-1045.	10.0	27
66	CXCL13 is androgen-responsive and involved in androgen induced prostate cancer cell migration and invasion. <i>Oncotarget</i> , 2017, 8, 53244-53261.	1.8	26
67	CDK2 and FOXO1: A Fork in the Road for Cell Fate Decisions. <i>Cell Cycle</i> , 2007, 6, 902-906.	2.6	25
68	Reduced Tumor Necrosis Factor Receptor-Associated Death Domain Expression Is Associated with Prostate Cancer Progression. <i>Cancer Research</i> , 2009, 69, 9448-9456.	0.9	25
69	A genome-scale CRISPR-Cas9 screening method for protein stability reveals novel regulators of Cdc25A. <i>Cell Discovery</i> , 2016, 2, 16014.	6.7	25
70	Zinc finger protein 191 inhibits hepatocellular carcinoma metastasis through discs large 1-mediated yes-associated protein inactivation. <i>Hepatology</i> , 2016, 64, 1148-1162.	7.3	24
71	RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis. <i>Theranostics</i> , 2019, 9, 3459-3475.	10.0	22
72	ATM-phosphorylated SPOP contributes to 53BP1 exclusion from chromatin during DNA replication. <i>Science Advances</i> , 2021, 7, .	10.3	22

#	ARTICLE	IF	CITATIONS
73	SPOP mutation induces DNA methylation via stabilizing GLP/G9a. <i>Nature Communications</i> , 2021, 12, 5716.	12.8	19
74	Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer. <i>Theranostics</i> , 2019, 9, 5020-5034.	10.0	18
75	Mutated SPOP E3 Ligase Promotes 17 β HSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression. <i>Cancer Research</i> , 2021, 81, 3593-3606.	0.9	18
76	Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia. <i>Nature Communications</i> , 2019, 10, 5051.	12.8	17
77	An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors. <i>Cell Reports</i> , 2021, 34, 108744.	6.4	17
78	RNF12 promotes p53-dependent cell growth suppression and apoptosis by targeting MDM2 for destruction. <i>Cancer Letters</i> , 2016, 375, 133-141.	7.2	16
79	Lineage plasticity-mediated therapy resistance in prostate cancer. <i>Asian Journal of Andrology</i> , 2019, 21, 241.	1.6	15
80	ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	14
81	SPOP mutation induces replication over-firing by impairing Geminin ubiquitination and triggers replication catastrophe upon ATR inhibition. <i>Nature Communications</i> , 2021, 12, 5779.	12.8	14
82	ASPP1/2-PP1 complexes are required for chromosome segregation and kinetochore-microtubule attachments. <i>Oncotarget</i> , 2015, 6, 41550-41565.	1.8	14
83	GLI3 Is Stabilized by SPOP Mutations and Promotes Castration Resistance via Functional Cooperation with Androgen Receptor in Prostate Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 62-76.	3.4	14
84	3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O α -TM ^{PROTAC} . <i>Chemical Communications</i> , 2022, 58, 2383-2386.	4.1	13
85	Epidaurus: aggregation and integration analysis of prostate cancer epigenome. <i>Nucleic Acids Research</i> , 2015, 43, e7-e7.	14.5	10
86	Detecting the H3F3A mutant allele found in high-grade pediatric glioma by real-time PCR. <i>Journal of Neuro-Oncology</i> , 2016, 126, 27-36.	2.9	10
87	Cyclophilin J limits inflammation through the blockage of ubiquitin chain sensing. <i>Nature Communications</i> , 2018, 9, 4381.	12.8	10
88	Protocol to apply spike-in ChIP-seq to capture massive histone acetylation in human cells. <i>STAR Protocols</i> , 2021, 2, 100681.	1.2	10
89	Microenvironment-Mediated Resistance to Anti-Androgen Therapy. <i>Cancer Cell</i> , 2020, 38, 155-157.	16.8	9
90	Estrogen receptor beta repurposes EZH2 to suppress oncogenic NF κ B/p53 signaling in triple negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 20.	5.2	9

#	ARTICLE	IF	CITATIONS
91	Re-Evaluate Fusion Genes in Prostate Cancer. <i>Cancer Informatics</i> , 2021, 20, 117693512110275.	1.9	5
92	MAP3K7-IKK Inflammatory Signaling Modulates AR Protein Degradation and Prostate Cancer Progression. <i>Cancer Research</i> , 2021, 81, 4471-4484.	0.9	5
93	Activity of NEO2734, a novel dual inhibitor of both BET and CBP-P300, in SPOP-mutated prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 62-62.	1.6	4
94	Fat lure: adipocytes attract cancer cells out of the prostate. <i>Translational Cancer Research</i> , 2016, 5, S123-S125.	1.0	3
95	PMEPA1 guards against TGF- β ² -mediated prostate cancer bone metastasis. <i>Asian Journal of Urology</i> , 2016, 3, 1-3.	1.2	1
96	Androgen receptor: Functional roles and facets of regulation in urology. <i>Asian Journal of Urology</i> , 2020, 7, 189-190.	1.2	1
97	Scaffold attachment factor B1: an intrinsic inhibitor of androgen receptor downregulated in prostate cancer. <i>Asian Journal of Andrology</i> , 2013, 15, 703-704.	1.6	1
98	Enhancer of zeste-homolog 2 (EZH2) expression and clinical outcomes in metastatic castrate resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 350-350.	1.6	0